Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II Study of FCN-338 in Relapsed or Refractory B-cell Lymphoma
ChiCTR2300073346Phase 2Recruiting
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of LOXO-338 in malignant B-cell neoplasm, mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL) and 1 more (2 arms), sponsored by Peking University Cancer Hospital & Institute. Primary endpoints: Objective response rate, Safety: dose-limiting toxicities during DLT observation period and 2 more. Started Feb 2022; status: recruiting.
02
Drugs
LOXO-338
03
Conditions
malignant B-cell neoplasmmantle cell lymphoma (MCL)diffuse large B-cell lymphoma (DLBCL)mature B-cell lymphoma
Beyond the preview
Go deeper on ChiCTR2300073346.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300073346.